All Alzheimer's articles
-
Opinion
Welcome to the MegaPharm target selection and project resourcing meeting
Overheard recently in a seminar room near you…
-
Business
Europe reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
-
Opinion
Letters: September 2024
Readers discuss antidepressants, industrial disasters and what Humphry Davy inhaled
-
Opinion
Being wrong is almost inevitable
On the tightrope of expressing your opinion, you always risk looking a fool
-
Research
New mechanism identified that is potentially linked to very early stages of Alzheimer’s
Understanding role of fragments of amyloid protein could lead to novel therapies for the disease
-
Feature
How microbes influence our brain health
Our gut microbiome has been linked to conditions such as Parkinson’s and Alzheimer’s. Anthony King reports on the connections
-
Opinion
From one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
Research
Rare medical transmission of Alzheimer’s disease from donor to patient discovered
Human growth hormone extracted from cadavers passed disease protein to at least five people
-
Business
Pharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
Opinion
Moving beyond protein structure
Efforts to understand how intrinsically disordered regions interact have produced a variety of answers
-
Opinion
Letters: September 2023
Readers estimate the contribution of lithium mining on power consumption, consider Alzheimer’s antibody therapies and more
-
Business
Antibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
Business
Biogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
Research
Tell-tale protein fragment discovered in Alzheimer’s patients could be basis for blood test
Tau protein fragment could track progress of the disease
-
Opinion
Regulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
Business
Second Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
Business
Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
Opinion
Alzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
Opinion
When regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients